John O Mascarenhas

72PUBLICATIONS
224CO-AUTHORS
Haematological tumoursRegenerative medicine (incl. stem cells)Proteins and peptidesMedical virologyEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (72)

|Aug 20, 2026
Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

|Aug 19, 2026
Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms.

|Jun 02, 2026
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

|May 18, 2026
Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

|Apr 15, 2026
Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR), With del(5q) and Double Minutes Containing Chromosomal Segment 11q24 Leading to Amplification and Expression of FLI1.

Satomi Hiya, Joseph Tripodi, John Mascarenhas

|Mar 17, 2026
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

John O Mascarenhas, Laura Maria Fogliatto, Steven D Green

Pageof 12

Frequent Collaborators

9 joint publications

Vikas K Gupta

9 joint publications

Alessandro Maria Vannucchi

8 joint publications

Jean-Jacques Kiladjian

7 joint publications

Srdan Verstovsek